By John Vandermosten, CFA

CNSX:ORTH.CN | OTC:ORTIF

READ THE FULL ORTH.CN RESEARCH REPORT

Clinical Hold Letter Lifted

Following the April 2021 Investigational New Drug (IND) submission for Ortho-R, Ortho Regenerative Technologies Inc. (CSE:ORTH) (OTC:ORTIF) notified the public on December 13th that the FDA had lifted its Clinical Hold on the application. Two months after its IND submission, Ortho announced that a clinical hold had been placed on the trial launch pending the collection of additional chemistry, manufacturing and control (CMC) related data and characterization of the chitosan product. On July 20th, Ortho announced that it had formally...